Image pharmaphorum Editor News Biogen’s Alzheimer’s drug, elenbecestat, shows early promise A trial of Biogen’s Alzheimer’s disease drug elenbecestat has had promising results in mild to moderate forms of the disease. Views & Analysis Patient centricity makes ethical and commercial sense Patient centricity is no longer a buzzword, it’s an essential way of conducting business that makes both ethical and commercial sense. Views & Analysis Disease spotlight: Duchenne muscular dystrophy (DMD) News Migraine prevention drug Aimovig poised for EU approval The first antibody treatment to prevent migraine (Aimovig), produced by Novartis, is on the cusp of approval. Load more results
News Biogen’s Alzheimer’s drug, elenbecestat, shows early promise A trial of Biogen’s Alzheimer’s disease drug elenbecestat has had promising results in mild to moderate forms of the disease.
Views & Analysis Patient centricity makes ethical and commercial sense Patient centricity is no longer a buzzword, it’s an essential way of conducting business that makes both ethical and commercial sense.
News Migraine prevention drug Aimovig poised for EU approval The first antibody treatment to prevent migraine (Aimovig), produced by Novartis, is on the cusp of approval.
News In brief SOTU remarks, Trump asks Congress to "codify" MFN In a speech at least nominally focused on the economy and affordability, President Trump put surprisingly little emphasis on his drug pricing efforts.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
